News | Stents Bifurcation | September 21, 2017

Tryton Side Branch Stent Recognized With Premier Technology Breakthrough Award

Stent is first dedicated bifurcation device to receive U.S. regulatory approval

Tryton Side Branch Stent Recognized With Premier Technology Breakthrough Award

September 21, 2017 — Cardinal Health and Tryton Medical Inc. announced that the Tryton coronary Side Branch Stent was recognized by healthcare improvement company Premier Inc. with the Technology Breakthrough Award. Premier’s Technology Breakthrough Award is granted to cutting-edge products that significantly advance healthcare in terms of safety, clinical outcomes and/or operational efficiency.

The Tryton Side Branch Stent, the first dedicated bifurcation device to receive regulatory approval in the United States, is approved for the treatment of de novo coronary bifurcation lesions involving large side branches (appropriate for a ≥2.5mm stent). Cordis, Cardinal Health’s interventional vascular business, is the exclusive U.S. distributor of the Tryton Side Branch Stent. 

The Tryton Side Branch Stent System is built using Tri-Zone technology for treating bifurcation lesions. Tryton’s cobalt chromium stent is deployed in the side branch artery using a standard single wire balloon-expandable stent delivery system. A conventional drug-eluting stent is then placed in the main vessel.

For more information: www.trytonmedical.com

Related Content

News | Cath Lab

October 6, 2021 — Boston Scientific Corp. announced it entered into a definitive agreement to acquire Baylis Medical ...

Home October 06, 2021
Home
News | Cath Lab

September 21, 2021 — Medtronic is recalling its Pipeline Flex Embolization Device and Pipeline Flex Embolization Device ...

Home September 21, 2021
Home
Feature | Cath Lab | By Aaron Detate and Lars Thording

In the electrophysiology (EP) lab, hundreds of thousands of used devices are sent to reprocessors every year to get ...

Home September 14, 2021
Home
News | Cath Lab

July 22, 2021 — Medis Medical Imaging is partnering with CORRIB Core Lab and Sinomed in randomized clinical trial of ...

Home July 22, 2021
Home
News | Cath Lab

July 13, 2021 — East End Medical announced it received U.S. Food and Drug Administration (FDA) clearance for the company ...

Home July 14, 2021
Home
Feature | Cath Lab | By Dave Fornell, Editor

There is a trend in interventional cardiology that is now being called “renalism,” where patients with poor renal ...

Home May 14, 2021
Home
News | Cath Lab

May 12, 2021 — Abbott recently announced its new interventional imaging platform powered by Ultreon 1.0 Software, has ...

Home May 12, 2021
Home
Feature | Cath Lab | By Dave Fornell, Editor

April 29, 2021 — Here is the list of late-breaking study presentations and links to articles about each of them from the ...

Home May 06, 2021
Home
Videos | Cath Lab

Ashwin Nathan M.D., a cardiology fellow in the division of Cardiovascular Medicine at the Hospital of the University of ...

Home May 05, 2021
Home
News | Cath Lab

May 3, 2021 – Results from a new study find a broad range of patients who typically undergo revascularization for stable ...

Home May 03, 2021
Home
Subscribe Now